187 related articles for article (PubMed ID: 25310995)
1. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?
Bastin J; Bonnefont JP; Djouadi F; Bresson JL
J Inherit Metab Dis; 2015 Mar; 38(2):371-2. PubMed ID: 25310995
[No Abstract] [Full Text] [Related]
2. No effect of bezafibrate in patients with CPTII and VLCAD deficiencies.
Ørngreen MC; Vissing J; Laforét P
J Inherit Metab Dis; 2015 Mar; 38(2):373-4. PubMed ID: 25331908
[No Abstract] [Full Text] [Related]
3. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.
Ørngreen MC; Madsen KL; Preisler N; Andersen G; Vissing J; Laforêt P
Neurology; 2014 Feb; 82(7):607-13. PubMed ID: 24453079
[TBL] [Abstract][Full Text] [Related]
4. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
Yamada K; Taketani T
J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency.
Shiraishi H; Yamada K; Egawa K; Ishige M; Ochi F; Watanabe A; Kawakami S; Kuzume K; Watanabe K; Sameshima K; Nakamagoe K; Tamaoka A; Asahina N; Yokoshiki S; Kobayashi K; Miyakoshi T; Oba K; Isoe T; Hayashi H; Yamaguchi S; Sato N
Brain Dev; 2021 Feb; 43(2):214-219. PubMed ID: 32798077
[TBL] [Abstract][Full Text] [Related]
6. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders.
Djouadi F; Bastin J
J Inherit Metab Dis; 2008 Apr; 31(2):217-25. PubMed ID: 18392740
[TBL] [Abstract][Full Text] [Related]
7. Strategies for correcting very long chain acyl-CoA dehydrogenase deficiency.
Tenopoulou M; Chen J; Bastin J; Bennett MJ; Ischiropoulos H; Doulias PT
J Biol Chem; 2015 Apr; 290(16):10486-94. PubMed ID: 25737446
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestations and enzymatic activities of mitochondrial respiratory chain complexes in Pearson marrow-pancreas syndrome with 3-methylglutaconic aciduria: a case report and literature review.
Sato T; Muroya K; Hanakawa J; Iwano R; Asakura Y; Tanaka Y; Murayama K; Ohtake A; Hasegawa T; Adachi M
Eur J Pediatr; 2015 Dec; 174(12):1593-602. PubMed ID: 26074369
[TBL] [Abstract][Full Text] [Related]
9. Prolonged QT interval and lipid alterations beyond β-oxidation in very long-chain acyl-CoA dehydrogenase null mouse hearts.
Gélinas R; Thompson-Legault J; Bouchard B; Daneault C; Mansour A; Gillis MA; Charron G; Gavino V; Labarthe F; Des Rosiers C
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H813-23. PubMed ID: 21685264
[TBL] [Abstract][Full Text] [Related]
10. Genetic characteristics and follow-up of patients with fatty acid β-oxidation disorders through expanded newborn screening in a Northern Chinese population.
Wang S; Leng J; Diao C; Wang Y; Zheng R
J Pediatr Endocrinol Metab; 2020 May; 33(6):683-690. PubMed ID: 32447334
[TBL] [Abstract][Full Text] [Related]
11. Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.
Everard E; Laeremans H; Boemer F; Marie S; Vincent MF; Dewulf JP; Debray FG; De Laet C; Nassogne MC
Eur J Paediatr Neurol; 2024 Mar; 49():60-65. PubMed ID: 38377647
[TBL] [Abstract][Full Text] [Related]
12. Very long-chain acyl-coenzyme A dehydrogenase deficiency in Chinese patients: eight case reports, including one case of prenatal diagnosis.
Li X; Ding Y; Ma Y; Liu Y; Wang Q; Song J; Yang Y
Eur J Med Genet; 2015 Mar; 58(3):134-9. PubMed ID: 25652019
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.
Janeiro P; Jotta R; Ramos R; Florindo C; Ventura FV; Vilarinho L; Tavares de Almeida I; Gaspar A
Eur J Pediatr; 2019 Mar; 178(3):387-394. PubMed ID: 30617651
[TBL] [Abstract][Full Text] [Related]
14. A primigravida with very-long-chain acyl-CoA dehydrogenase deficiency.
Murata KY; Sugie H; Nishino I; Kondo T; Ito H
Muscle Nerve; 2014 Feb; 49(2):295-6. PubMed ID: 23966064
[No Abstract] [Full Text] [Related]
15. Pearson syndrome in a Diamond-Blackfan anemia cohort.
Alter BP
Blood; 2014 Jul; 124(3):312-3. PubMed ID: 25035146
[TBL] [Abstract][Full Text] [Related]
16. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?
Djouadi F; Aubey F; Schlemmer D; Gobin S; Laforet P; Wanders RJ; Strauss AW; Bonnefont JP; Bastin J
J Inherit Metab Dis; 2006; 29(2-3):341-2. PubMed ID: 16763897
[TBL] [Abstract][Full Text] [Related]
17. Muscle MRI in patients with long-chain fatty acid oxidation disorders.
Diekman EF; van der Pol WL; Nievelstein RA; Houten SM; Wijburg FA; Visser G
J Inherit Metab Dis; 2014 May; 37(3):405-13. PubMed ID: 24305961
[TBL] [Abstract][Full Text] [Related]
18. Different Lipid Signature in Fibroblasts of Long-Chain Fatty Acid Oxidation Disorders.
Alatibi KI; Hagenbuchner J; Wehbe Z; Karall D; Ausserlechner MJ; Vockley J; Spiekerkoetter U; Grünert SC; Tucci S
Cells; 2021 May; 10(5):. PubMed ID: 34069977
[TBL] [Abstract][Full Text] [Related]
19. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes.
Bleeker JC; Kok IL; Ferdinandusse S; van der Pol WL; Cuppen I; Bosch AM; Langeveld M; Derks TGJ; Williams M; de Vries M; Mulder MF; Gozalbo ER; de Sain-van der Velden MGM; Rennings AJ; Schielen PJCI; Dekkers E; Houtkooper RH; Waterham HR; Pras-Raves ML; Wanders RJA; van Hasselt PM; Schoenmakers M; Wijburg FA; Visser G
J Inherit Metab Dis; 2019 May; 42(3):414-423. PubMed ID: 30761551
[TBL] [Abstract][Full Text] [Related]
20. Bezafibrate for an inborn mitochondrial beta-oxidation defect.
Bonnefont JP; Bastin J; Behin A; Djouadi F
N Engl J Med; 2009 Feb; 360(8):838-40. PubMed ID: 19228633
[No Abstract] [Full Text] [Related]
[Next] [New Search]
